# B7-H3 (CD276) expression

Source: https://onco.cc/biomarkers/b7-h3-expression/  
OnCo record `b7-h3-expression` (Biomarker). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

B7-H3 is an immune checkpoint protein overexpressed on small-cell lung, prostate and many solid tumours. Ifinatamab deruxtecan is in phase 3 for small-cell lung cancer without an expression cut-off; nothing is approved.

## Summary

Ifinatamab deruxtecan (I-DXd) is being compared with topotecan or other chemotherapy in relapsed small-cell lung cancer in IDeate-Lung02 (NCT06203210) with no B7-H3 selection; earlier phase studies found responses across expression levels. Other B7-H3 ADCs and radioligands are in early trials. No regulator has approved a B7-H3-directed drug.

## Fields

- Kind: Biomarker
- Last checked: 2026-09-23
- Also known as: B7-H3; CD276 expression; B7-H3 positive
- Tags: biomarker; surface-antigen; no-threshold

## Sources

- ClinicalTrials.gov NCT06203210 (IDeate-Lung02): https://clinicaltrials.gov/study/NCT06203210

## Connected records

- biomarkers: [DLL3 expression](https://onco.cc/biomarkers/dll3-expression/)
- cancers: [Extensive-stage small-cell lung cancer](https://onco.cc/cancers/extensive-stage-sclc/), [Metastatic castration-resistant prostate cancer](https://onco.cc/cancers/prostate-mcrpc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Ifinatamab deruxtecan](https://onco.cc/drugs/ifinatamab-deruxtecan/)
- targets: [B7-H3](https://onco.cc/targets/b7h3/)

---
JSON: https://onco.cc/api/v1/entities/b7-h3-expression.json